NYSEAMERICAN:CANF - CAN-FITE BIOPHA/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.54 +0.04 (+8.00 %)
(As of 04/25/2019 04:00 PM ET)
Previous Close$0.50
Today's Range$0.49 - $0.55
52-Week Range$0.45 - $1.73
Volume366,400 shs
Average Volume313,228 shs
Market Capitalization$10.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. has a collaborative research agreement with the Icahn School of Medicine for therapeutic discovery of liver diseases. The company was founded in 1994 and is headquartered in Petah-Tikva, Israel.

Receive CANF News and Ratings via Email

Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CANF
CUSIPN/A
Phone+972-3-9241114

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees7
Market Cap$10.79 million
Next Earnings Date6/7/2019 (Estimated)
OptionableOptionable

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) Frequently Asked Questions

What is CAN-FITE BIOPHA/S's stock symbol?

CAN-FITE BIOPHA/S trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CANF."

How were CAN-FITE BIOPHA/S's earnings last quarter?

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) posted its quarterly earnings data on Wednesday, April, 8th. The biotechnology company reported ($0.20) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.05. View CAN-FITE BIOPHA/S's Earnings History.

When is CAN-FITE BIOPHA/S's next earnings date?

CAN-FITE BIOPHA/S is scheduled to release their next quarterly earnings announcement on Friday, June 7th 2019. View Earnings Estimates for CAN-FITE BIOPHA/S.

What price target have analysts set for CANF?

2 brokers have issued 1-year price targets for CAN-FITE BIOPHA/S's stock. Their forecasts range from $8.00 to $8.00. On average, they expect CAN-FITE BIOPHA/S's stock price to reach $8.00 in the next year. This suggests a possible upside of 1,381.5% from the stock's current price. View Analyst Price Targets for CAN-FITE BIOPHA/S.

What is the consensus analysts' recommendation for CAN-FITE BIOPHA/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CAN-FITE BIOPHA/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CAN-FITE BIOPHA/S.

What are Wall Street analysts saying about CAN-FITE BIOPHA/S stock?

Here are some recent quotes from research analysts about CAN-FITE BIOPHA/S stock:
  • 1. HC Wainwright analysts commented, "We reiterate our Buy rating and 12-month price target (PT) of $3. Our PT was derived by using a 25% rate to discount free cash flows from annual sales and royalty payments of piclidenoson in RA and psoriasis for each year and dividing them by our projected number of shares for each year to account for the effects of share dilution, and then factoring in a 1% terminal growth rate and 65% clinical program probability of success." (3/27/2019)
  • 2. According to Zacks Investment Research, "Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate is being developed for the treatment of liver diseases and its CF602 drug is being developed for the treatment of inflammation and sexual dysfunction. Can Fite Biopharma Ltd. is based in Petach Tikva, Israel. " (2/5/2019)

Has CAN-FITE BIOPHA/S been receiving favorable news coverage?

News articles about CANF stock have trended somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. CAN-FITE BIOPHA/S earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.

Are investors shorting CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S saw a drop in short interest in April. As of April 15th, there was short interest totalling 449,405 shares, a drop of 58.8% from the March 29th total of 1,090,756 shares. Based on an average daily trading volume, of 520,626 shares, the short-interest ratio is currently 0.9 days. View CAN-FITE BIOPHA/S's Current Options Chain.

Who are some of CAN-FITE BIOPHA/S's key competitors?

What other stocks do shareholders of CAN-FITE BIOPHA/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CAN-FITE BIOPHA/S investors own include BIOLINERX LTD/S (BLRX), Novavax (NVAX), TransEnterix (TRXC), AEterna Zentaris (AEZS), Iovance Biotherapeutics (IOVA), Opko Health (OPK), TherapeuticsMD (TXMD), Athersys (ATHX), Cancer Genetics (CGIX) and Conatus Pharmaceuticals (CNAT).

Who are CAN-FITE BIOPHA/S's key executives?

CAN-FITE BIOPHA/S's management team includes the folowing people:
  • Dr. Ilan Cohn, Co-Founder & Chairman (Age 65)
  • Prof. Pnina Fishman, Scientific Founder, CEO & Director (Age 71)
  • Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 55)
  • Dr. Sari Fishman Ph.D., VP of Bus. Devel. (Age 47)
  • Dr. Vibeke Strand M.D., FACP, FACR (USA), Sr. Clinical Advisor

How do I buy shares of CAN-FITE BIOPHA/S?

Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CAN-FITE BIOPHA/S's stock price today?

One share of CANF stock can currently be purchased for approximately $0.54.

How big of a company is CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S has a market capitalization of $10.79 million. CAN-FITE BIOPHA/S employs 7 workers across the globe.

What is CAN-FITE BIOPHA/S's official website?

The official website for CAN-FITE BIOPHA/S is http://www.canfite.co.il.

How can I contact CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S's mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The biotechnology company can be reached via phone at +972-3-9241114.


MarketBeat Community Rating for CAN-FITE BIOPHA/S (NYSEAMERICAN CANF)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  128 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  226
MarketBeat's community ratings are surveys of what our community members think about CAN-FITE BIOPHA/S and other stocks. Vote "Outperform" if you believe CANF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CANF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Featured Article: Municipal Bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel